MDT

86.79

+0.46%↑

113.49

-1.49%↓

VEEV

171.56

-1.05%↓

HQY

81.28

-2.94%↓

PHR.US

9.16

+2.69%↑

MDT

86.79

+0.46%↑

113.49

-1.49%↓

VEEV

171.56

-1.05%↓

HQY

81.28

-2.94%↓

PHR.US

9.16

+2.69%↑

MDT

86.79

+0.46%↑

113.49

-1.49%↓

VEEV

171.56

-1.05%↓

HQY

81.28

-2.94%↓

PHR.US

9.16

+2.69%↑

MDT

86.79

+0.46%↑

113.49

-1.49%↓

VEEV

171.56

-1.05%↓

HQY

81.28

-2.94%↓

PHR.US

9.16

+2.69%↑

MDT

86.79

+0.46%↑

113.49

-1.49%↓

VEEV

171.56

-1.05%↓

HQY

81.28

-2.94%↓

PHR.US

9.16

+2.69%↑

Home・Akciju saraksts・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Atvērts

3.94 -1.01

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

3.73

Max

3.99

Galvenie mērījumi
By Trading Economics
Ienākumi	466K -27M
Pārdošana	2M 15M
Peļņas marža	-178.834
Darbinieki	141
EBITDA	-2M -29M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+270.45% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 4. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	2.1M 231M
Iepriekšējā atvēršanas cena	4.95
Iepriekšējā slēgšanas cena	3.94

Tehniskais rādītājs

By Trading Central

Pārliecība

Bearish Evidence

3.17 / 3.4644 Atbalsts un pretestība

Voyager Therapeutics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 6. apr. 23:17 UTC

Peļņas

Samsung Forecasts Record First-Quarter Operating Profit

2026. g. 6. apr. 23:00 UTC

Karstas akcijas

Stocks to Watch: Health Insurers, Mawson, Owlet

2026. g. 6. apr. 22:13 UTC

Galvenie tirgus virzītāji

Health Insurance Shares Gain on 2.48% Medicare Rate Bump

2026. g. 6. apr. 21:46 UTC

Iegādes, apvienošanās, pārņemšana

BP 'Optimizes Portfolio' and Sells 13 Thorntons Stores to Giant Oil -- OPIS

2026. g. 6. apr. 17:09 UTC

Galvenie tirgus virzītāji

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

2026. g. 6. apr. 16:56 UTC

Galvenie ziņu notikumi

U.S. Released 1.5 Million Bbls of Crude From SPR Last Week, DOE Data Show -- OPIS

2026. g. 6. apr. 14:47 UTC

Galvenie tirgus virzītāji

Stereotaxis Shares Rise on FDA Clearance for Synchrony

2026. g. 7. apr. 00:00 UTC

Galvenie ziņu notikumi

Ukraine's Lesson for Trump: Military Dominance Opens Waterways -- WSJ

2026. g. 6. apr. 23:58 UTC

Tirgus saruna

Galvenie ziņu notikumi

Iran War Will Keep Oil Prices High Through 2Q, Says Westpac -- Market Talk

2026. g. 6. apr. 23:50 UTC

Tirgus saruna

Nikkei May Rise on Hopes for Iran Cease-Fire -- Market Talk

2026. g. 6. apr. 23:36 UTC

Tirgus saruna

Gold Edges Higher as Investors Focus on U.S.-Iran Conflict -- Market Talk

2026. g. 6. apr. 23:15 UTC

Tirgus saruna

RBA Won't Raise Rates as Australia's Economy Softens Fast -- Market Talk

2026. g. 6. apr. 22:52 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2026. g. 6. apr. 22:52 UTC

Tirgus saruna

Pro Medicus Unlikely to Complete New Buyback in Full -- Market Talk

2026. g. 6. apr. 22:14 UTC

Tirgus saruna

Correction to Live Cattle Futures Article

2026. g. 6. apr. 20:56 UTC

Tirgus saruna

Mexican Private Consumption Fell in January -- Market Talk

2026. g. 6. apr. 20:50 UTC

Tirgus saruna

Energy & Utilities Roundup: Market Talk

2026. g. 6. apr. 20:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 6. apr. 19:58 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 6. apr. 19:58 UTC

Tirgus saruna

Live Cattle Futures Hit Record High, Hogs Edge Up -- Market Talk

2026. g. 6. apr. 19:11 UTC

Tirgus saruna

U.S. Natural Gas Edges Up in Rangebound Trade -- Market Talk

2026. g. 6. apr. 19:06 UTC

Tirgus saruna

Treasury Yields Decline as a Belligerent Trump Talks to Reporters -- Market Talk

2026. g. 6. apr. 19:03 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2026. g. 6. apr. 19:03 UTC

Tirgus saruna

Crude Futures Edge Up As Trump's Iran Deadline Nears -- Market Talk

2026. g. 6. apr. 18:36 UTC

Iegādes, apvienošanās, pārņemšana

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

2026. g. 6. apr. 17:59 UTC

Tirgus saruna

Galvenie ziņu notikumi

Travel Booking Companies Facing More Demand Uncertainty Than Expected -- Market Talk

2026. g. 6. apr. 17:13 UTC

Iegādes, apvienošanās, pārņemšana

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

2026. g. 6. apr. 16:33 UTC

Tirgus saruna

Oil Futures Steady as Market Awaits Trump -- Market Talk

2026. g. 6. apr. 16:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2026. g. 6. apr. 14:59 UTC

Peļņas

Strategy Records a $14.5 Billion Unrealized Loss in First Quarter -- WSJ

Salīdzinājums

Cenas izmaiņa

Voyager Therapeutics Inc Prognoze

Cenas mērķis

By TipRanks

270.45% augšup

Prognoze 12 mēnešiem

Vidējais 14.67 USD 270.45%

Augstākais 25 USD

Zemākais 8 USD

Pamatojoties uz 8 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Voyager Therapeutics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

8 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 8 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Voyager Therapeutics Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

3.17 / 3.4644Atbalsts un pretestība

Recent bearish events outweigh bullish events.

All events are bearish.

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.